CellOrigin Biotech
CellOrigin Biotech is a Hangzhou-based, privately held biotech developing off-the-shelf iPSC-derived CAR-macrophage and CAR-NK cell therapies for cancer immunotherapy, using its proprietary iPSC-CAR-Macrophage Technology Platform and in-house GMP manufacturing.
- Company typePrivate
- Founded2018
- HeadquartersHangzhou, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CellOrigin Biotech does
CellOrigin Biotech (legal name CellOrigin Inc.) is a Hangzhou, China-based, privately held biotech founded in 2018 that develops off-the-shelf immune cell therapies for cancer using induced pluripotent stem cell (iPSC) technology. The company's core scientific bet is that innate immune cells — specifically macrophages and natural killer (NK) cells — engineered with chimeric antigen receptors (CARs) and derived from a renewable iPSC source can be manufactured at scale as standardized, off-the-shelf products, bypassing the patient-specific manufacturing burden of conventional autologous CAR-T therapies.
The company's product pipeline centers on two modalities: iPSC-derived CAR-macrophage cells and iPSC-derived CAR-NK cells, both intended for cancer immunotherapy. These candidates are developed and produced on CellOrigin's proprietary iPSC-CAR-Macrophage Technology Platform, which integrates cell line engineering with in-house CMC (Chemistry, Manufacturing, and Controls) development and is supported by proprietary GMP manufacturing facilities. The platform architecture is positioned as a foundation for expanding the innate immune cell pipeline and for enabling scalable, consistent off-the-shelf supply, although no products have reached commercialization as of the available data.
CellOrigin's business model is a clinical-stage biotech model with no current product revenue. The company intends to monetize through commercialization of off-the-shelf engineered immune cell therapies to cancer patients via hospital and cancer treatment center channels, and is funded through venture capital. Disclosed funding includes an investment from Kunlun Capital in 2021 to support CMC development, a roughly 100 million RMB (~$15.7M) round in March 2022 from EFung Capital, Kunlun Capital, LYFE Capital, and Yinxinggu Capital, and a subsequent round in September 2023 involving Haiyuan Capital and Yuhang State Investment. The company is classified as operating but its corporate website (en.cell-origin.com) was reported as expired, which is a notable operational signal.
CellOrigin Biotech firmographics
Firmographics- Name
- CellOrigin Biotech
- Legal name
- CellOrigin Inc.
- Website
- https://en.cell-origin.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CellOrigin Biotech is a Hangzhou-based, privately held biotech developing off-the-shelf iPSC-derived CAR-macrophage and CAR-NK cell therapies for cancer immunotherapy, using its proprietary iPSC-CAR-Macrophage Technology Platform and in-house GMP manufacturing.
- Ownership category
- akta.pro rank
CellOrigin Biotech industry classification
Industry- Product category
- Cell Therapy / Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where CellOrigin Biotech is headquartered
LocationHeadquarters
- HQ city
- Hangzhou
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
CellOrigin Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain
Revenue model
- Off-the-shelf Immune Cell Therapies: The company is developing and plans to commercialize off-the-shelf iPSC-derived immune cell products for cancer immunotherapy, including CAR-macrophage and CAR-NK cell therapies.
Go-to-market motion1 record
CellOrigin Biotech product offering
Product offeringCore offering
CellOrigin Biotech develops off-the-shelf iPSC-derived innate immune cell therapeutics for cancer immunotherapy. Its core products are CAR-macrophage and CAR-NK cells engineered from induced pluripotent stem cells (iPSCs), manufactured using proprietary GMP facilities and CMC development capabilities for use in oncology treatment.
Product overview
CellOrigin Biotech is a platform-based biotech company developing off-the-shelf iPSC-derived immune cell therapies for cancer. The company operates its proprietary iPSC-CAR-Macrophage Technology Platform to engineer and manufacture CAR-macrophage and CAR-NK cell products for cancer immunotherapy. The core products include CAR-Macrophage and CAR-NK cell candidates engineered from induced pluripotent stem cells (iPSCs), with the company utilizing its GMP manufacturing facilities to advance these immune cell therapies toward clinical trials.
Differentiator
Problem solved
Functional benefit
Products and services
- CAR-Macrophage
Companies that use CellOrigin Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
CellOrigin Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CellOrigin Biotech partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
CellOrigin Biotech competitors and assessment
Company assessmentDirect peers
- Shoreline Biosciences: Developer of iPSC-derived allogeneic NK cell therapies for cancer with multiple pharma partnerships (e.g., Kite). Closely comparable iPSC-NK platform to CellOrigin's CAR-NK program.
- Allogene Therapeutics: Pioneer in allogeneic CAR-T cell therapies with multiple clinical-stage assets. Comparable off-the-shelf cell therapy positioning and oncology focus, though centered on T cells rather than NK/macrophages.
- Nkarta: Clinical-stage biotech developing allogeneic NK cell therapies, including iPSC-derived and engineered NK platforms, for cancer. Directly comparable in NK modality and allogeneic delivery model.
- Fate Therapeutics: Clinical-stage US biotech developing iPSC-derived off-the-shelf NK and T-cell cancer immunotherapies. Closest direct competitor to CellOrigin given shared iPSC platform, allogeneic modality, and oncology focus.
- Cytovia Therapeutics: Clinical-stage developer of NK cell and macrophage-based cancer immunotherapies, including iPSC-derived candidates. Closely comparable to CellOrigin's dual NK/macrophage modality focus.
- Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable off-the-shelf engineered cell therapy approach, though centered on T cells.
- Century Therapeutics: US-based clinical-stage company engineering iPSC-derived allogeneic cell therapies (NK and T cells) with gene edits to enhance persistence and safety. Directly comparable platform approach to CellOrigin.
Broad incumbents
- Legend Biotech: Global commercial-stage cell therapy company (BCMA CAR-T, Carvykti) with a broad allogeneic pipeline and deep pharma partnership with Johnson & Johnson. Relevant incumbent scale comparator for the broader engineered cell therapy category.
Regional players
- JW Therapeutics: China-headquartered cell therapy company with a commercial autologous CD19 CAR-T (Carteyva) and expanding pipeline. Direct China-region comparator that highlights both regulatory pathway learnings and competitive pressure within Chinese oncology.
- CARsgen Therapeutics: China-based clinical-stage cell therapy developer with CAR-T programs including allogeneic candidates. Regional competitor relevant for understanding the China cell therapy development landscape.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
CellOrigin Biotech social profiles
Digital presenceCellOrigin Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellOrigin Biotech leadership team
Management profileNumber of profiles
CellOrigin Biotech funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellOrigin Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellOrigin Biotech
What does CellOrigin Biotech do?
CellOrigin Biotech develops off-the-shelf iPSC-derived innate immune cell therapeutics for cancer immunotherapy. Its core products are CAR-macrophage and CAR-NK cells engineered from induced pluripotent stem cells (iPSCs), manufactured using proprietary GMP facilities and CMC development capabilities for use in oncology treatment.
Is CellOrigin Biotech a public or private company?
CellOrigin Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was CellOrigin Biotech founded?
CellOrigin Biotech was founded in 2018. It employs 51 to 100 people.
Where is CellOrigin Biotech based?
CellOrigin Biotech is headquartered in Hangzhou, China, in the Asia region.
How does CellOrigin Biotech make money?
One revenue line is on record: off-the-shelf Immune Cell Therapies.
Who are CellOrigin Biotech's main competitors?
Direct peers on record are Shoreline Biosciences, Allogene Therapeutics, Nkarta, Fate Therapeutics, Cytovia Therapeutics, Caribou Biosciences and Century Therapeutics. Legend Biotech is listed as a broad incumbent. Regional players are JW Therapeutics and CARsgen Therapeutics.
Does CellOrigin Biotech have an API?
No public API is recorded for CellOrigin Biotech.
What industry is CellOrigin Biotech in?
CellOrigin Biotech's product category is Cell Therapy / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.